These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 2271340)

  • 1. A systemic non-lytic state and local thrombolytic failure of anistreplase (anisoylated plasminogen streptokinase activator complex, APSAC) in acute myocardial infarction.
    Brügemann J; van der Meer J; Takens BH; Hillege H; Lie KI
    Br Heart J; 1990 Dec; 64(6):355-8. PubMed ID: 2271340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
    Johnson ES; Cregeen RJ
    Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic effects of anisoylated plasminogen streptokinase activator complex and streptokinase therapy in acute myocardial infarction. Coagulation aspects of the Dutch Invasive Reperfusion Study.
    Hoffmann JJ; Bonnier JJ; de Swart JB; Custers P; Vijgen M
    Drugs; 1987; 33 Suppl 3():242-6. PubMed ID: 3315602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Haematological effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():247-52. PubMed ID: 2445540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
    Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics, thrombolytic efficacy and hemorrhagic risk of different streptokinase regimens in heparin-treated acute myocardial infarction.
    Col JJ; Col-De Beys CM; Renkin JP; Lavenne-Pardonge EM; Bachy JL; Moriau MH
    Am J Cardiol; 1989 May; 63(17):1185-92. PubMed ID: 2653017
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J
    Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of 2 intravenous thrombolytic agents (anisoylated plasminogen streptokinase activator complex versus streptokinase) in patients with acute myocardial infarction.
    Seabra-Gomes R; Aniceto Silva J; Aleixo A; Real T; Freire I; Torres I; Freitas R; Crespo F
    Drugs; 1987; 33 Suppl 3():169-74. PubMed ID: 3315586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of time to treatment on early infarct-related artery patency after different thrombolytic regimens. ALKK-Study Group.
    Zeymer U; Tebbe U; Essen Rv; Haarmann W; Neuhaus KL
    Am Heart J; 1999 Jan; 137(1):34-8. PubMed ID: 9878934
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the thrombolytic activity of the novel plasminogen activator, LY210825, to anisoylated plasminogen-streptokinase activator complex in a canine model of coronary artery thrombolysis.
    Jackson CV; Frank JD; Craft TJ; Sundboom JL; Smith GF
    J Pharmacol Exp Ther; 1992 Jan; 260(1):64-70. PubMed ID: 1731052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coronary thrombolysis during acute myocardial infarction by intravenous BRL 26921, a new anisoylated plasminogen-streptokinase activator complex.
    Kasper W; Meinertz T; Wollschläger H; Bonzel T; Wolff P; Drexler H; Hofmann T; Zeiher A; Just H
    Am J Cardiol; 1986 Sep; 58(6):418-21. PubMed ID: 3529908
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical effects and kinetic properties of intravenous APSAC--anisoylated plasminogen-streptokinase activator complex (BRL 26921) in acute myocardial infarction.
    Been M; de Bono DP; Muir AL; Boulton FE; Fears R; Standring R; Ferres H
    Int J Cardiol; 1986 Apr; 11(1):53-61. PubMed ID: 3514485
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
    Clin Trials Metaanal; 1993 Nov; 28(6):317-28. PubMed ID: 10150180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of anistreplase on coronary patency in acute myocardial infarction].
    Pacouret G; Charbonnier B
    Arch Mal Coeur Vaiss; 1990 Feb; 83 Spec No 1():25-9. PubMed ID: 2108643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lack of influence of pretreatment antistreptokinase antibody on efficacy in a multicenter patency comparison of intravenous streptokinase and anistreplase in acute myocardial infarction.
    Fears R; Hearn J; Standring R; Anderson JL; Marder VJ
    Am Heart J; 1992 Aug; 124(2):305-14. PubMed ID: 1636574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravenous anisoylated plasminogen streptokinase activator complex versus intravenous streptokinase in evolving myocardial infarction. Preliminary data from a randomised multicentre study.
    Brochier ML; Quilliet L; Kulbertus H; Materne P; Letac B; Cribier A; Monassier JP; Sacrez A; Favier JP
    Drugs; 1987; 33 Suppl 3():140-5. PubMed ID: 3315581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized trial of intravenous heparin in conjunction with anistreplase (anisoylated plasminogen streptokinase activator complex) in acute myocardial infarction: the Duke University Clinical Cardiology Study (DUCCS) 1.
    O'Connor CM; Meese R; Carney R; Smith J; Conn E; Burks J; Hartman C; Roark S; Shadoff N; Heard M
    J Am Coll Cardiol; 1994 Jan; 23(1):11-8. PubMed ID: 8277068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.